Drug Profile

Recombinant coagulation factor X - VarmX

Alternative Names: Factor Xa inhibitor reversal agent - VarmX; Modified blood coagulation factor X - VarmX; PseudoXa; VMX-C001

Latest Information Update: 23 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator VarmX
Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
Mechanism of Action Blood coagulation factor replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Blood coagulation disorders
No development reported Haemorrhage

Most Recent Events

31 Dec 2024 VarmX plans a phase II/III trial in early 2024 (VarmX pipeline, June 2025)
07 Dec 2024 Pharmacodynamics data from preclinical trials in Blood coagulation disorders presented at the 66^th American Society of Hematology Annual Meeting and Exposition (ASH-2024)
28 Nov 2024 No recent reports of development identified for phase-I development in Haemorrhage(Combination therapy, In volunteers) in Netherlands (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com